References
- Adams, J. H. 2023, May 3. The varieties of ‘psychedelic decriminalization. The challenging psychedelic experiences project. Accessed May 5, 2023. https://www.ecstaticintegration.org/p/the-varieties-of-psychedelic-decriminalization
- Aday, J. S., E. K. Bloesch, and C. C. Davoli. 2020. A year of expansion in psychedelic research, industry, and deregulation. Drug Science, Policy and Law 6:1–6. 2019. doi:10.1177/2050324520974484.
- Andrews, T., and K. Wright. 2022. The frontiers of new psychedelic therapies: A survey of sociological themes and issues. Sociology Compass 16 (2):e12959. doi:10.1111/soc4.12959.
- Argento, E., M. E. Socias, K. Hayashi, J. Choi, L. Mackay, D. Christie, M. J. Milloy, and K. DeBeck. 2022. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting. The International Journal on Drug Policy 100:103518. doi:10.1016/j.drugpo.2021.103518.
- Ballotpedia. 2022. Colorado proposition 122, decriminalization and regulated access program for certain psychedelic plants and fungi initiative. Accessed February 3, 2023. https://ballotpedia.org/Colorado_Proposition_122,_Decriminalization_and_Regulated_Access_Program_for_Certain_Psychedelic_Plants_and_Fungi_Initiative_2022#Text_of_measure
- Boehnke, K. F., A. K. Davis, and J. McAfee. 2022. Applying lessons from cannabis to the psychedelic highway: Buckle up and build infrastructure. JAMA Health Forum 3 (6):e221618. doi:10.1001/jamahealthforum.2022.1618.
- Bogenschutz, M. P., A. A. Forcehimes, J. A. Pommy, C. E. Wilcox, P. C. Barbosa, and R. J. Strassman. 2015. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology 29 (3):289–99. doi:10.1177/0269881114565144.
- Cascio, J. 2022, September 21. First legal mushroom dispensary in U.S. opens in Ybor city. fox 13 news tampa bay. Accessed December 14, 2022. https://www.fox13news.com/news/first-legal-mushroom-dispensary-in-u-s-opens-in-ybor-city
- Cohen, I. G., and M. Marks. 2022, February 20. Patents on psychedelics: the next legal battlefront of drug development.HarvardLaw Review Accessed December 14, 2022. https://harvardlawreview.org/2022/02/patents-on-psychedelics-the-next-legal-battlefront-of-drug-development/
- Davis, A. K., F. S. Barrett, D. G. May, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, P. H. Finan, and R. R. Griffiths. 2021. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry 78 (5):481–89. doi:10.1001/jamapsychiatry.2020.3285.
- Doblin, R. 2023, January 23. Rick doblin – the balance at MAPS between public benefit and private profit – psychedelic alpha. psychedelic alpha. https://psychedelicalpha.com/news/rick-doblin-the-balance-at-maps-between-public-benefit-and-private-profit. Accessed April 29, 2023.
- Garcia-Romeu, A., A. K. Davis, E. Erowid, F. Erowid, R. R. Griffiths, and M. W. Johnson. 2020. Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Frontiers in Psychiatry 10:955. doi:10.3389/fpsyt.2019.00955.
- Garcia-Romeu, A., A. K. Davis, F. Erowid, E. Erowid, R. R. Griffiths, and M. W. Johnson. 2019. Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology 33 (9):1088–101. doi:10.1177/0269881119845793.
- Glynos, N. G., C. W. Fields, J. Barron, M. Herberholz, D. J. Kruger, and K. F. Boehnke. 2022. Naturalistic psychedelic use: A world apart from clinical care. Journal of Psychoactive Drugs: 1–10. Advance online publication. doi:10.1080/02791072.2022.2108356.
- Goodwin, G. M., S. T. Aaronson, O. Alvarez, P. C. Arden, A. Baker, J. C. Bennett, and E. Malievskaia, R. E. Blom, C. Brennan, D. Brusch. 2022. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine 387 (18):1637–48. doi:10.1056/NEJMoa2206443.
- Haijen, E. C. H. M., M. Kaelen, L. Roseman, C. Timmermann, H. Kettner, S. Russ, D. Nutt, R. E. Daws, A. D. G. Hampshire, R. Lorenz, et al., 2018. Predicting responses to psychedelics: A prospective study. Frontiers in Pharmacology 9:897. doi:10.3389/fphar.2018.00897.
- Hallifax, J. 2022, June 24. Compass Pathways psilocybin patent upheld. Psychedelic Spotlight. Accessed December 14, 2022. https://psychedelicspotlight.com/compass-pathways-psilocybin-patent/
- Hausfeld, R. 2020, September 15. As COMPASS pathways continues its attempts to build a psychedelic monopoly, Usona institute keeps publishing open research. Psymposia. Accessed December 14, 2022. https://www.psymposia.com/magazine/compass-psychedelic-psilocybin-patents-usona-open-science/
- Honig, E. 2019, May 9. In Close Vote, Denver Becomes 1st U.S. City to Decriminalize Psychedelic Mushrooms. Accessed December 14, 2022. https://www.npr.org/sections/health-shots/2019/05/09/721660053/in-close-vote-denver-becomes-first-u-s-city-to-decriminalize-psychedelic-mushroo
- Israel, B. A., C. M. Coombe, R. R. Cheezum, A. J. Schulz, R. J. McGranaghan, R. Lichtenstein, A. G. Reyes, J. Clement, and A. Burris. 2010. Community-based participatory research: A capacity-building approach for policy advocacy aimed at eliminating health disparities. American Journal of Public Health 100 (11):2094–102. doi:10.2105/AJPH.2009.170506.
- Johnson, M. W., A. Garcia-Romeu, and R. R. Griffiths. 2017. Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse 43 (1):55–60. doi:10.3109/00952990.2016.1170135.
- Kelly, J. G. 1971. Qualities for the community psychologist. American Psychologist 26 (10):897–903. doi:10.1037/h0032231.
- Lea, T., N. Amada, H. Jungaberle, H. Schecke, and M. Klein. 2020. Microdosing psychedelics: Motivations, subjective effects and harm reduction. The International Journal on Drug Policy 75:102600. doi:10.1016/j.drugpo.2019.11.008.
- Legislature, O. (2021). Chapter 475A — psilocybin regulation 2021 Edition. Accessed February 3, 2023. https://www.oregonlegislature.gov/bills_laws/ors/ors475A.html
- Lewin, K. 1946. Action research and minority problems. In Resolving social conflicts, selected papers on group dynamic,143–152. eds G. W. Lewin, Washington DC, USA: American Psychological Association. doi:10.1037/10269-013
- Life Sciences, A. 2022, January 12. Atai life sciences announces fda investigational new drug (ind) clearance for pcn-101 r-ketamine program. Accessed February 3, 2023. https://atai.life/2022/01/12/atai-life-sciences-announces-fda-investigational-new-drug-ind-clearance-for-pcn-101-r-ketamine-program/
- Life Sciences, A. 2023, January 9. Atai life sciences announces results from phase 2a trial of pcn-101 (r-ketamine) for treatment-resistant depression. Accessed April 20, 2023. https://atai.life/2023/01/09/atai-life-sciences-announces-results-from-phase-2a-trial-of-pcn-101-r-ketamine-for-treatment-resistant-depression/
- MacBride, K. 2021. Psychedelic-assisted therapy is bigger than ever, but it’s at risk of being compromised by alleged abuse. Accessed November 18, 2021.https://www.inverse.com/mind-body/grossbard-bourzat-psychedelic-assisted-therapy-abuse.
- Maybin, S., and J. Casserly. 2020, January 16. I was sexually abused by a shaman at an ayahuasca retreat. BBC News.Accessed April 20, 2023. https://www.bbc.com/news/stories-51053580.
- McNamee, S., N. Devenot, and M. Buisson. 2023. Studying harms is key to improving psychedelic-assisted therapy—participants call for changes to research Landscape. JAMA Psychiatry 80 (5):411. Published online March 29, 2023. doi:10.1001/jamapsychiatry.2023.0099.
- Mitchell, J. M., M. Bogenschutz, A. Lilienstein, C. Harrison, S. Kleiman, K. Parker-Guilbert, G. Ot’alora, M. Garas, W. Paleos, C. Gorman, et al., 2021. MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine 27 (6):1025–33. doi:10.1038/s41591-021-01336-3.
- Monroe, R. 2017, January 18. Sexual assault in the Amazon: As the ayahuasca tourism industry grows, so do accounts of abuse. New York Magazine. https://www.thecut.com/2021/11/sexual-assault-ayahuasca-tourism.html. Accessed April 20, 2023.
- Naftulin, J. 2020 November 4. Oregon has become the first state to legalize ‘magic’ mushrooms for therapeutic use. here’s what that means. Business Insider: Accessed December 14, 2022 https://www.businessinsider.com/oregon-first-ever-state-to-legalize-psilocybin-for-therapeutic-use-2020-11.
- Noorani, T. 2020. Making psychedelics into medicines: The politics and paradoxes of medicalization. Journal of Psychedelic Studies 4 (1):34–39. doi:10.1556/2054.2019.018.
- Nutt, D., M. Spriggs, and D. Erritzoe. 2023. Psychedelics therapeutics: What we know, what we think, and what we need to research. Neuropharmacology 223:109257. doi:10.1016/j.neuropharm.2022.109257.
- Psychedelic Alpha. 2022. Psychedelics Legalization & Decriminalization Tracker.Psychedelic Alpha. Accessed December 14, 2022. https://psychedelicalpha.com/data/psychedelic-laws.
- Rappaport, J. 1987. Terms of empowerment/exemplars of prevention: Toward a theory for community psychology. American Journal of Community Psychology 15 (2):121–48. doi:10.1007/BF00919275.
- Sessa, B. 2012. The psychedelic renaissance: reassessing the role of psychedelic drugs in 21st century psychiatry and society. London: Muswell Hill Press.
- Siegel, J. S., J. E. Daily, D. A. Perry, and G. E. Nicol. 2023. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry 80 (1):77–83. doi:10.1001/jamapsychiatry.2022.4101.
- Stanton, R. 2020, September 21. Ann Arbor OKs move to decriminalize psychedelic mushrooms, plants. Accessed December 14, 2022. https://www.mlive.com/news/ann-arbor/2020/09/ann-arbor-oks-move-to-decriminalize-psychedelic-mushrooms-plants.html
- Szigeti, B., L. Kartner, A. Blemings, F. Rosas, A. Feilding, D. J. Nutt, R. L. Carhart-Harris, and D. Erritzoe. 2021. Self-blinding citizen science to explore psychedelic microdosing. eLife 10:e62878. doi:10.7554/eLife.62878.
- U.S. Food and Drug Administration. 2019, March 9. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. Accessed January 11, 2032. https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
- Uthaug, M. V., A. K. Davis, T. F. Haas, D. Davis, S. B. Dolan, R. Lancelotta, C. Timmermann, and J. G. Ramaekers. 2022. The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. Journal of Psychopharmacology 36 (3):309–20. doi:10.1177/02698811211013583.
- Yockey, R. A., and K. King. 2021. Use of psilocybin (“mushrooms”) among US adults: 2015–2018. Journal of Psychedelic Studies 5 (1):17–21. doi:10.1556/2054.2020.00159.
- Yockey, R. A., R. A. Vidourek, and K. A. King. 2020. Trends in LSD use among US adults: 2015-2018. Drug and Alcohol Dependence 212:108071. doi:10.1016/j.drugalcdep.2020.108071.